Aflatoxin, hepatitis and worldwide liver cancer risks.

Aflatoxins are among the most potent mutagenic and carcinogenic substances known. Differential potency of aflatoxin among species can be partially attributed to differences in metabolism; however, current information on competing aspects of metabolic activation and detoxification of aflatoxin in various species does not identify an adequate animal model for humans. Risk of liver cancer is influenced by a number of factors, most notably carriage of hepatitis B virus as determined by the presence in serum of the hepatitis B surface antigen (HBsAg+ or HBsAg-). About 50 to 100% of liver cancer cases are estimated to be associated with persistent infection of hepatitis B (or C) virus. The potency of aflatoxin in HBsAg+ individuals is substantially higher (about a factor of 30) than the potency in HBsAg- individuals. Thus, reduction of the intake of aflatoxins in populations with a high prevalence of HBsAg+ individuals will have greater impact on reducing liver cancer rates than reductions in populations with a low prevalence of HbsAg+ individuals. The present analysis suggests that vaccination against hepatitis B (or protection against hepatits C), which reduces prevalence of carriers, would reduce the potency of the aflatoxins in vaccinated populations and reduce liver cancer risk.

[1]  A. Muñoz,et al.  Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[2]  D. Parkin.  The global burden of cancer. , 1998, Seminars in cancer biology.

[3]  Miriam J. Alter.  Epidemiology of hepatitis C. , 1996 .

[4]  J. Hoofnagle,et al.  Hepatitis C: The clinical spectrum of disease , 1997, Hepatology.

[5]  Joint Fao,et al.  Evaluation of certain food additives and contaminants. Forty-ninth report of the Joint FAO/WHO Expert Committee on Food Additives. , 1999, World Health Organization technical report series.

[6]  C. Boone,et al.  Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein. , 1998, Carcinogenesis.

[7]  A. Muñoz,et al.  Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  K. Yoo,et al.  Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. , 1998, International journal of epidemiology.

[9]  A. Hall,et al.  Primary prevention of hepatocellular carcinoma in developing countries. , 2000, Mutation research.

[10]  W. Edmunds,et al.  Developed countries could pay for hepatitis B vaccination in developing countries , 1998, BMJ.

[11]  F. X. Bosch,et al.  Epidemiology of Primary Liver Cancer , 1999, Seminars in liver disease.

[12]  A. Muñoz,et al.  Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. , 1999, Journal of the National Cancer Institute.

[13]  A. Valleron,et al.  Trends in primary liver cancer , 1998, The Lancet.

[14]  J. Hoofnagle,et al.  Dose‐finding study of interferon alfa‐n3 in hepatitis , 1997 .

[15]  Joint Fao,et al.  Book Review: Safety Evaluation of Certain Food Additives and Contaminants , 1999 .

[16]  M. Koffler.  Epidemiology of hepatitis. , 1965, Lancet.

[17]  N. Freimer,et al.  Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC‐1] and Byler syndrome): Evidence for heterogeneity , 1997, Hepatology.

[18]  P. Rao.  Who Food Additives Series , 1973 .

[19]  M. Gail,et al.  Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1 , 1999, Hepatology.